Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - tetanus toxoid, quantity: 40 iu; pertussis fimbriae 2 + 3, quantity: 5 microgram; diphtheria toxoid, quantity: 30 iu; poliovirus, quantity: 29 dagu; poliovirus, quantity: 26 dagu; poliovirus, quantity: 7 dagu; pertussis toxoid, quantity: 20 microgram; pertactin, quantity: 3 microgram; pertussis filamentous haemagglutinin, quantity: 20 microgram - injection, suspension - excipient ingredients: polymyxin b sulfate; bovine serum albumin; formaldehyde; phenoxyethanol; glutaral; neomycin; water for injections; polysorbate 80; aluminium phosphate - quadracel is indicated for primary immunisation of children from the age of 2 months to 12 months against diphtheria, tetanus, pertussis, and poliomyelitis.,quadracel is also indicated for the fourth dose for children from 15 months to six years of age who have been immunised previously with three doses of diphtheria, tetanus, pertussis and polio vaccines.

Australia - English - Department of Health (Therapeutic Goods Administration)

australian nuclear science and technology organisation t/a ansto - indium (111in) pentetate, quantity: 37 mbq/ml - injection, solution - excipient ingredients: water for injections; pentetic acid; sodium bicarbonate - indications as at 11 jan 05 : radionuclide cisternography.

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer (perth) pty ltd - idarubicin hydrochloride, quantity: 1 mg/ml - injection, solution - excipient ingredients: hydrochloric acid; glycerol; water for injections - belgium adults: zavedos is indicated in cases of blood cancer called acute myelogenous leukemia (aml) to induce remission, as a first-line treatment or in patients with relapse or a relapsing form of the disease. zavedos is indicated in adults suffering from a blood cancer called acute lymphoblastic leukemia (all) that has been previously treated. children: zavedos, in combination with cytarabine, is indicated as the first induction therapy for remission in children suffering from a blood cancer called acute myeloblastic leukemia (aml), previously untreated. zavedos is also indicated in children with a blood cancer called acute lymphoblastic leukemia (all) that has been previously treated. canada idamycin pfs (idarubicin hydrochloride injection) alone or in combination chemotherapy regimens involving other cytotoxic agents is indicated in: ? acute non-lymphocytic leukemia (anll); in adults for remission induction as front-line therapy or for remission induction in relapsed or refractory patients. ? acute lymphocytic leukemia (all) as second line treatment in adults and children. chile ? acute non-lymphocytic leukemia (anll); also called acute myelogenous leukemia (aml) in children and adults for remission induction as first-line therapy or for remission induction in relapsed or refractory patients. ? acute lymphocytic leukemia (all) as second-line treatment in adults and children. colombia adjunct in the treatment of acute myelogenous leukemia (aml) in adults and second line treatment for acute lymphocytic leukemia (all) in adults and children. ecuador acute non-lymphocytic leukemia (anll; also referred to as acute myelogenous leukemia [aml]) in adults for remission induction as first-line therapy or for remission induction in relapsed or refractory patients. acute lymphocytic leukemia (all) as second-line treatment in adults and children. finland zavedos is used for the treatment of acute myeloid leukaemia (a type of blood cancer) in adults. zavedos, in combination with cytarabin, is indicated for the first remission induction treatment in previously not treated children with acute mylogenous leukaemia (aml). france zavedos solution for infusion is indicated for the treatment of acute myeloid leukemia. zavedos solution for infusion is indicated for the treatment of acute lymphoblastic leukemia in relapse. zavedos solution for infusion in combination with cytarabine, is indicated for the induction treatment of first remission in previously untreated children with blood cancer called acute myeloid leukemia (aml). germany adults zavedos is indicated for use in combination with other cytostatics (such as cytabarine) for the treatment (remission induction and consolidation) of adult patients with acute myeloid leukaemia (aml, anll) who have not received any previous treatment. children and adolescents zavedos, in combination with cytarabine, is indicated for first-line remission induction treatment of children with blood cancer, called acute myeloid leukaemia (aml), who have not received any previous treatment. italy zavedos is used: ? in adults and children as treatment for acute myeloid leukaemia, a blood cancer; ? in adults and children as treatment for acute lymphocytic leukaemia, a blood cancer, when previous treatments did not work or were inadequate. malaysia acute non-lymphocytic leukemia (anll) in adults for remission induction in untreated patients, or for remission induction in relapsed or refractory patients, acute lymphocytic leukemia (all) as second line treatment in adults and children. netherlands adults acute myeloblastic leukaemia (aml): for remission induction as first line treatment or for remission induction in relapsed or refractory patients. acute lymphoblastic leukaemia (all): second line treatment. children acute myeloblastic leukaemia (aml): for remission induction as first line treatment, in combination with cytarabine. acute lymphoblastic leukaemia (all): second line treatment. poland adults: - acute non-lymphocytic leukemia [anll, also referred to as acute myelogenous leukemia (aml)] for remission induction as first-line therapy or for remission induction in relapsed or refractory patients. - acute lymphocytic leukemia (all) as second line treatment. children: - acute myeloid leukemia (aml) in combination with cytarabine, as first line therapy for remission induction. - acute lymphocytic leukemia (all) as second line treatment. singapore zavedos is indicated for use in acute myelogenous leukaemia (aml) in adults for remission induction in untreated patients or for remission induction in relapsed or refractory patients. zavedos may be used in combination chemotherapy regimens involving other cytotoxic agents. slovak republic use in adults: acute myeloblastic leukemia (aml) for induction of remission (induction mitigation until disappearance of disease symptoms): - in the first line of aml treatment, - in patients with aml relapse (aggravation or development of previous status), - for non-responding amls, - acute lymphoblastic leukemia (all) as a second-line treatment. use in children: - acute myeloblastic leukemia (aml) for induction of remission in combination with cytarabine as the first line of treatment, - acute lymphoblastic leukemia (all) as a second-line treatment. switzerland acute myeloid leukaemia in combination with other cytostatics. acute lymphatic leukaemia as reserve medication in combination with other cytostatics. thailand zavedos is indicated for use in acute myelogenous leukaemia (aml) in adults for remission induction in untreated patients or for remission induction in relapsed or refractory patients. zavedos may be used in combination chemotherapy regimens involving other cytotoxic agents. united kingdom adults for the treatment of acute myeloid leukaemia (aml), for remission induction in untreated patients or for remission induction in relapsed or refractory patients. for second line treatment of relapsed acute lymphoblastic leukaemia (all). paediatric population for first line treatment of acute myeloid-leukaemia (aml), in combination with cytarabine, for remission induction. for second line treatment of relapsed acute lymphoblastic leukaemia (all). zavedos may be used in combination chemotherapy regimens involving other cytotoxic agents

Australia - English - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - docetaxel, quantity: 80 mg - injection, concentrated - excipient ingredients: polysorbate 80; ethanol absolute; citric acid - breast cancer docetaxel is indicated for the treatment of patients with locally advanced or metastatic breast cancer in whom previous chemotherapy has failed. docetaxel in combination with capecitabine is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior anthracycline containing chemotherapy. docetaxel in combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer whose tumours overexpress her2 and who previously have not received chemotherapy for metastatic disease adjuvant treatment of breast cancer docetaxel in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with node-positive breast cancer. doxorubicin and cyclophosphamide followed by docetaxel in combination with trastuzumab (ac-th) is indicated for the adjuvant treatment of patients with operable breast cancer whose tumours overexpress her2. docetaxel in combination with carboplatin and trastuzumab (tch) is indicated for the adjuvant treatment of patients with operable breast cancer whose tumours overexpress her2 docetaxel in combination with cyclophosphamide is indicated for the adjuvant treatment of operable breast cancer with a primary tumour of = 1 cm and < 7 cm. non small cell lung cancer docetaxel is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer, including those who have failed platinum-based chemotherapy. ovarian cancer docetaxel is indicated for the treatment of metastatic carcinoma of the ovary after failure of first-line or subsequent chemotherapy. prostate cancer docetaxel is indicated for the treatment of patients with androgen independent (hormone refractory) prostate cancer. head and neck cancer docetaxel in combination with cisplatin and fluorouracil, is indicated as induction treatment prior to chemoradiotherapy, for the treatment of patients with locally advanced, squamous cell carcinoma of the head and neck, who have low probability of surgical cure, require organ preservation or where the tumour is technically unresectable.

Australia - English - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - docetaxel, quantity: 160 mg - injection, concentrated - excipient ingredients: citric acid; ethanol absolute; polysorbate 80 - breast cancer docetaxel is indicated for the treatment of patients with locally advanced or metastatic breast cancer in whom previous chemotherapy has failed. docetaxel in combination with capecitabine is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior anthracycline containing chemotherapy. docetaxel in combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer whose tumours overexpress her2 and who previously have not received chemotherapy for metastatic disease adjuvant treatment of breast cancer docetaxel in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with node-positive breast cancer. doxorubicin and cyclophosphamide followed by docetaxel in combination with trastuzumab (ac-th) is indicated for the adjuvant treatment of patients with operable breast cancer whose tumours overexpress her2. docetaxel in combination with carboplatin and trastuzumab (tch) is indicated for the adjuvant treatment of patients with operable breast cancer whose tumours overexpress her2 docetaxel in combination with cyclophosphamide is indicated for the adjuvant treatment of operable breast cancer with a primary tumour of = 1 cm and < 7 cm. non small cell lung cancer docetaxel is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer, including those who have failed platinum-based chemotherapy. ovarian cancer docetaxel is indicated for the treatment of metastatic carcinoma of the ovary after failure of first-line or subsequent chemotherapy. prostate cancer docetaxel is indicated for the treatment of patients with androgen independent (hormone refractory) prostate cancer. head and neck cancer docetaxel in combination with cisplatin and fluorouracil, is indicated as induction treatment prior to chemoradiotherapy, for the treatment of patients with locally advanced, squamous cell carcinoma of the head and neck, who have low probability of surgical cure, require organ preservation or where the tumour is technically unresectable.

Saudi Arabia - English - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

novocol, canada - articaine,norepinephrine bitartrate - injection - 40,0.009 mg/ml,

United Arab Emirates - English - MOHAP (Ministry of Health & Prevention) - وزارة الصحة ووقاية المجتمع.الإمارات

arabian ethicals co. canada - 1 glass vial - injection - 3.5mg/vial - n/a-n/a

United Arab Emirates - English - MOHAP (Ministry of Health & Prevention) - وزارة الصحة ووقاية المجتمع.الإمارات

orex medical trading l l c canada - 2's (2 x 1ml pre filled syringes ) - injection - 25mg/ml - skin-n/a

United Arab Emirates - English - MOHAP (Ministry of Health & Prevention) - وزارة الصحة ووقاية المجتمع.الإمارات

orex medical trading l l c canada - 2's (2 x 1ml pre filled syringes ) - injection - 25mg/ml - skin-n/a

United Arab Emirates - English - MOHAP (Ministry of Health & Prevention) - وزارة الصحة ووقاية المجتمع.الإمارات

pharmalink store canada - 1 glass vial [80 mg/4 ml] - injection - 20 mg/ml - malignant disease,immunosuppresion-cytotoxics